Annexon, Inc. (NASDAQ:ANNX - Get Free Report) Director William H. Carson acquired 3,200 shares of the firm's stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average price of $6.07 per share, with a total value of $19,424.00. Following the acquisition, the director now directly owns 3,200 shares in the company, valued at $19,424. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Annexon Stock Down 1.0 %
Shares of Annexon stock opened at $6.17 on Thursday. The firm's 50 day moving average price is $5.70 and its 200-day moving average price is $3.93. Annexon, Inc. has a 52-week low of $1.57 and a 52-week high of $8.40. The company has a market cap of $555.49 million, a P/E ratio of -3.47 and a beta of 1.14.
Analysts Set New Price Targets
A number of equities research analysts recently weighed in on ANNX shares. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Annexon in a report on Wednesday, March 27th. JPMorgan Chase & Co. raised their target price on shares of Annexon from $11.00 to $13.00 and gave the company an "overweight" rating in a research report on Monday, April 1st. Needham & Company LLC reissued a "buy" rating and set a $16.00 target price on shares of Annexon in a research report on Wednesday, March 27th. Bank of America raised their target price on shares of Annexon from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Thursday, March 28th. Finally, Wells Fargo & Company raised their target price on shares of Annexon from $11.00 to $12.00 and gave the company an "overweight" rating in a research report on Wednesday, March 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $14.43.
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
Get Our Latest Report on ANNX
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of ANNX. BVF Inc. IL purchased a new position in shares of Annexon in the 4th quarter worth approximately $31,780,000. Bain Capital Life Sciences Investors LLC grew its position in shares of Annexon by 41.4% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company's stock worth $36,600,000 after buying an additional 2,359,793 shares during the last quarter. BlackRock Inc. grew its position in shares of Annexon by 199.7% in the 2nd quarter. BlackRock Inc. now owns 3,479,896 shares of the company's stock worth $12,249,000 after buying an additional 2,318,780 shares during the last quarter. Federated Hermes Inc. grew its position in shares of Annexon by 50.7% in the 1st quarter. Federated Hermes Inc. now owns 3,052,651 shares of the company's stock worth $8,334,000 after buying an additional 1,027,051 shares during the last quarter. Finally, Kennedy Capital Management LLC purchased a new stake in Annexon during the 3rd quarter worth approximately $2,306,000.
Annexon Company Profile
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
